Saga Investments LLC
http://www.decode.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Saga Investments LLC
Verve Not Ready To Pull Plug On Anti-PCSK9 Gene Editing Candidate
The company told Scrip that the sixth patient with elevated liver enzymes and low platelets recovered after hospital observation and oral steroids, and it may still continue VERVE-101’s development.
Conflicts Of Interest Delay Leqembi’s EU Approval
Eisai/Biogen’s Alzheimer’s drug has fallen foul of a recent court ruling over the handling of the European Medicines Agency’s experts' competing interests.
Leqembi’s EU Approval Process Delayed Over Advisory Group COI Considerations
The EU regulatory agency’s discussions for lecanemab’s approval are hit by a decision to annul advice from an advisory committee due to the implications of a Court of Justice ruling on the handling of experts' competing interests.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Company Information
- Other Names / Subsidiaries
-
- deCODE genetics ehf
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice